Bortezomib consolidation post ‐ASCT as frontline therapy for multiple myeloma deepens disease response and MRD‐negative rate whilst maintaining QOL and response to re‐treatment at relapse
British Journal of Haematology, EarlyView.
Source: British Journal of Haematology - Category: Hematology Authors: Oliver C. Cohen,
Nicholas Counsell,
Neil Rabin,
Rakesh Popat,
Roger G. Owen,
Bilyana Popova,
Oliver Schofield,
Laura Clifton ‐Hadley,
Janet Lyons‐Lewis,
Andy Rawstron,
Christopher Spence,
Ruth M. Tute,
Derralynn Hughes,
Sally Moore,
Paul Tags: Correspondence Source Type: research